Abstract |
The clinical pharmacokinetics and exposure-toxicity relationship were determined for EC145, a conjugate of folic acid and the Vinca alkaloid desacetylvinblastine hydrazide (DAVLBH), in cancer patients. EC145 plasma concentration and toxicity data were obtained from a first-in-man phase I study and analyzed by nonlinear mixed effect modeling with NONMEM. EC145 concentration-time profile after intravenous administration was well described by a 2-compartment model with a first-order elimination process from the central compartment. BSA was identified as a significant covariate on EC145 clearance, accounting for 14.6% of interindividual variation on EC145 clearance. Population estimates for the clearance, steady-state volume of distribution, distribution, and elimination half-lives were 56.1 L/h, 26.1 L, 6 minutes, and 26 minutes, respectively. Constipation and peripheral neuropathy were the most common and clinically relevant toxicities. The clearance and area under the concentration-time curve (AUC) were significant predictors for the incidence of EC145-induced constipation but not peripheral neuropathy. In conclusion, EC145 is rapidly distributed and eliminated in cancer patients. BSA is a statistically significant covariate on EC145 clearance, but its clinical relevance remains to be defined. EC145-induced constipation occurs at a higher frequency in the patients with lower EC145 clearance, where the drug exposure tends to be higher.
|
Authors | Jing Li, Edward A Sausville, Patrick J Klein, David Morgenstern, Christopher P Leamon, Richard A Messmann, Patricia LoRusso |
Journal | Journal of clinical pharmacology
(J Clin Pharmacol)
Vol. 49
Issue 12
Pg. 1467-76
(Dec 2009)
ISSN: 1552-4604 [Electronic] England |
PMID | 19837906
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Carrier Proteins
- EC145
- Folate Receptors, GPI-Anchored
- Receptors, Cell Surface
- Vinca Alkaloids
- 4-desacetylvinblastine hydrazide
- Vinblastine
- Folic Acid
|
Topics |
- Adult
- Aged
- Body Surface Area
- Carrier Proteins
(metabolism)
- Constipation
(chemically induced)
- Female
- Folate Receptors, GPI-Anchored
- Folic Acid
(administration & dosage, adverse effects, analogs & derivatives, blood, pharmacokinetics)
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Neoplasms
(metabolism)
- Nonlinear Dynamics
- Peripheral Nervous System Diseases
(chemically induced)
- Receptors, Cell Surface
(metabolism)
- Vinblastine
(analogs & derivatives, blood)
- Vinca Alkaloids
(administration & dosage, adverse effects, blood, pharmacokinetics)
|